Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Oct. 17 — The White House's “moonshot” initiative to transform cancer care taps into industry giants from Microsoft and Amazon Web Services to ridesharing services Uber and Lyft, under a plan released Oct. 17.
Vice President Joe Biden presented to President Barack Obama the final report of the cancer moonshot task force—an interagency group forming the federal plan to try to achieve a decade’s worth of progress in five years—along with his own personal report. The policy and regulatory changes in the task force report range from new drug approvals to patent reform, the arts, defense research and the environment, said Greg Simon, the executive director of the cancer moonshot task force. Simon also announced a number of private-sector initiatives.
“Today marks a banner day for the cancer moonshot with the release of the task force report,” Simon said. By culminating the work of more than 20 White House Cabinet and subcabinet agencies that have been meeting since February, he said, the report sets “a new standard for what it means to be involved in the fight against cancer.” The report itself said the task force marks the first time this many government agencies are collaborating to “to tackle the challenges along the spectrum of cancer research and care to improve outcomes for patients.”
Biden, who is leading the moonshot initiative, said medical technologies and treatment plans had progressed rapidly, even since his late son Beau was diagnosed with and later succumbed to cancer.
“The fundamental thing I've come away with is there is a need for a greater sense of urgency because there are available answers now to some cancers and there is enormous opportunity in sharing data,” Biden said at a White House event to release the moonshot reports.
He expressed confidence medical advances with lead to new prevention technology.
“I look forward to the day when your grandchildren and my grandchildren and their children show up at the office to get their physical to start school and they get a shot for measles. They get a vaccine that affects significant [types] of cancers. We are very close to reaching that point.” Biden pledged, “I'm gonna devote the rest of my life to working on this, and I think we're perilously close to making some gigantic progress.”
Jon Retzlaff, managing director of science policy and government affairs for the American Association for Cancer Research, told Bloomberg BNA, “We’re extremely excited now that we have all the material and justification for moving forward and for communicating to policymakers why the cancer moonshot initiative needs to be supported and adequate funding provided.”
The president's budget request for fiscal year 2017 includes $755 million for new cancer-related research activities at both the National Institutes of Health and the Food and Drug Administration. Simon said the administration doesn't plan on changing its budget request and added there's no single, target number for achieving all the goals of the moonshot.
“One, it’s not all about money. A lot of it is about collaboration, culture change and process change in the federal government and in the private sector,” he said. “Secondly, the moonshot still has a long way to go in terms of laying out activities for the next year that will help us achieve our goal of getting a decade’s worth of progress in the prevention, diagnosis and treatment of cancer in five years.”
Retzlaff said there should be both robust funding for the moonshot in 2017 and for the long term. “This is not a just a one-time influx of dollars,” he told Bloomberg BNA. “This has to be sustained over time for us to achieve the goals that have been set out.”
The task force report listed five strategic goals to:
The report listed programs already underway at federal agencies, such as the new Oncology Center of Excellence at the FDA to streamline review and get new cancer therapies to patients more quickly, and a final rule to make more clinical trials information publicly available.
Ellen Sigal, founder of Friends of Cancer Research, cited the new FDA center as an example of tangible progress from the moonshot in breaking down barriers and connecting experts to accelerate treatments and heighten patient input.
“How far we have come heartens and humbles me. But we are just getting started. Complacency is not an option,” Sigal said in remarks to begin the White House event for the report's release. She called for redoubling efforts to achieve the cancer moonshot goals. “What does that mean? It means holding fast to the conviction that every patient matters, that we must never fail to listen to them or recognize their humanity.”
The more than 30 private-sector commitments Simon announced include:
The task force report also folded in the scientific agenda issued in September by a separate blue ribbon panel (10 LSLR 18, 9/16/16).
On the government side, the task force highlighted:
Moving forward, Simon said, the Department of Health and Human Services is considering adopting an open-access policy that could significantly affect how scientists publish their findings. Removing barriers to data sharing has been identified as a priority of the moonshot.
“HHS, NIH and NCI are currently reviewing the means by which we can require that government funded research be published in open access journals so that there’s not a delay between the publication of meaningful data and its accessibility to the general public as well as the scientific community,” Simon said.
Publishers have argued that they need to recoup the expensive, timely process of peer review required for each manuscript, which they have said can run thousands of dollars per article.
The Journal of the American Medical Association said in an Oct. 17 statement sent to Bloomberg BNA that it is fully compliant with NIH policies on public access. “All research articles are made free public access [six] months after publication without any author fees,” the statement said. “In addition, all articles are free public access on The JAMA Network Reader—also without any author fees. In addition, authors of research articles may deposit copies of their articles in PubMed Central for free public access [six] months after publication.”
—With assistance from Cheryl Bolen
To contact the reporter on this story: Jeannie Baumann in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Randy Kubetin at email@example.com
The task force report is at https://www.whitehouse.gov/sites/default/files/docs/final-whcmtf-report-1012161.pdf.
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)